{"id":802,"date":"2024-12-14T19:25:12","date_gmt":"2024-12-14T19:25:12","guid":{"rendered":"http:\/\/cetaitdemain.org\/?p=802"},"modified":"2024-12-14T19:25:12","modified_gmt":"2024-12-14T19:25:12","slug":"processed-and-purified-fab2-fragments-were-used-as-passive-immunotherapy-for-the-current-trial-supplying-them-in-vials-manufactured-with-gmp-standards-and-labelled-as-inm005-12","status":"publish","type":"post","link":"https:\/\/cetaitdemain.org\/?p=802","title":{"rendered":"\ufeffProcessed and purified F(ab)2 fragments were used as passive immunotherapy for the current trial, supplying them in vials manufactured with GMP standards and labelled as INM005 [12]"},"content":{"rendered":"

\ufeffProcessed and purified F(ab)2 fragments were used as passive immunotherapy for the current trial, supplying them in vials manufactured with GMP standards and labelled as INM005 [12]. or hospital discharge at day 28 (primary end-point), this analysis favored patients in the INM005 group at days 7 to 21. Also, a statistically significant less time to improvement (at least two ordinal categories or hospital discharge) was noted in the INM005 group. Among those with severe disease at baseline, a not statistically significant difference AS8351<\/a> in mortality was observed among patients receiving INM005 versus those receiving placebo. A greater benefit from INM005 was observed in those with non-reactive antibodies versus those with positive antibodies at baseline. Importantly, INM005 displayed a good safety profile and no serious adverse reactions were associated with it; none of the patients developed anaphylaxis. Implications of all the available evidence Effective therapeutic approaches for patients with severe COVID-19 disease are urgently needed. The administration of INM005 was associated with clinical benefits, especially in the subgroup of patients with severe COVID-19 disease as well as in those with delayed immune response measured by the absence of IgG anti-SARS-CoV-2 at study entry. Future studies will help to define the final role of this treatment in the context of current COVID-19 pandemic. AS8351 Alt-text: Unlabelled box 1.?Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is currently generating a global pandemic with more than 91 million infections and 1?9 million fatalities (as of January 2021) [1]. In Argentina, SARS-CoV-2 has caused more than 1?7 million infections and around 44,000 deaths. So far, dexamethasone [2,3] and remdesivir [4], [5], [6] have shown efficacy in adequately powered clinical trials. In addition, passive immunotherapy appears as a promising therapeutic approach, particularly for early stages of the disease in which patients have not yet established their specific immune response. To date, convalescent plasma (CP) has been the only antibody-based therapy widely available for COVID-19 patients, mainly through extended and compassionate use. This strategy has consistently shown an adequate safety profile, although no effect has been exhibited in the treatment of patients with severe pneumonia, while it may have a role in the treatment of elder patients within 72?h of initiation of symptoms of COVID-19 [7], [8], [9]. CP poses the additional troubles of the donor selection process and apheresis, the need of high titers of neutralizing antibodies (NAbs) and the potential limitation for scalability. As an Layn<\/a> alternative approach for immune therapy, different anti-receptor binding domain name (RBD) human monoclonal antibodies (mAbs) have been evaluated in the treatment of COVID-19 [10]. Although some degree of activity was observed in patients with moderate disease, no AS8351 consistent effect has been exhibited so far in hospitalized patients with moderate and severe disease [11]. It has been previously shown that this RBD from the viral spike glycoprotein elicits high titers of NAbs against SARS-CoV-2 when used as immunogen in horses [12]. In this regard, equine polyclonal antibodies (EpAbs) can represent a practical and efficient source of NAbs. EpAbs are composed of F(ab)2 fragments generated by pepsin digestion. These fragments retain the bivalent binding capacity of IgG immunoglobulins but lack the constant region (Fc), responsible for serum sickness reactions and Fc-triggered side effects. EpAbs recognize a vast array of epitopes (limiting the risk of viral escape mutations) and tend to develop greater avidity than mAbs for their cognate antigens. In addition, EpAbs are relatively easy to manufacture allowing a fast development and scaling up for a treatment. We have previously described the development and characterization of a therapeutic based on purified equine anti-RBD F(ab)2 fragments, called INM005 [12]. INM005 shows a very high serum AS8351 neutralization titer against SARS-CoV-2 and its format, devoid of Fc domains, may show preferable for.<\/p>\n","protected":false},"excerpt":{"rendered":"

\ufeffProcessed and purified F(ab)2 fragments were used as passive immunotherapy for the current trial, supplying them in vials manufactured with GMP standards and labelled as INM005 [12]. or hospital discharge at day 28 (primary end-point), this analysis favored patients in the INM005 group at days 7 to 21. Also, a statistically significant less time to …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-802","post","type-post","status-publish","format-standard","hentry","category-phosphoinositide-specific-phospholipase-c","entry entry-center"],"_links":{"self":[{"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=\/wp\/v2\/posts\/802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=802"}],"version-history":[{"count":1,"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=\/wp\/v2\/posts\/802\/revisions"}],"predecessor-version":[{"id":803,"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=\/wp\/v2\/posts\/802\/revisions\/803"}],"wp:attachment":[{"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=802"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=802"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=802"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}